Dermatology | Phase II Developments | UNITED STATES

Alpine Immune Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Alpine Immune Sciences Announces $60 Million Private Placement

Lead Product(s): ALPN-101

Therapeutic Area: Dermatology Product Name: ALPN-101

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Omega Funds

Deal Size: $60.0 million Upfront Cash: Undisclosed

Deal Type: Private Placement July 24, 2020

Details:

Funds gathered from the Private Placement will support Alpine Immune's two clinical-stage programs in ALPN-101 and ALPN-202, and a third program, ALPN-303.

Arcutis Biotherapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Arcutis Enrolls Last Patient in Phase 2b Clinical Trial Evaluating ARQ-154 as a Potential Treatment for Scalp Psoriasis

Lead Product(s): Roflumilast

Therapeutic Area: Dermatology Product Name: ARQ-154

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 20, 2020

Details:

Roflumilast foam is a once-daily topical foam formulation of a highly potent and selective phosphodiesterase type 4 inhibitor (PDE4 inhibitor) that the Company is developing particularly to treat inflammatory dermatoses in hair-bearing areas of the body such as the scalp.

Arcutis Biotherapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Arcutis Initiates Patient Enrollment in the Phase 2b Portion of the Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand Eczema

Lead Product(s): ARQ-252

Therapeutic Area: Dermatology Product Name: ARQ-252

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 13, 2020

Details:

Arcutis initiated enrollment in the Phase 2b portion of the Phase 1/2b study of ARQ-252, a potent and highly selective topical small molecule inhibitor of Janus kinase type 1 (JAK1), in adult patients with chronic hand eczema.

Concert Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Concert Pharmaceuticals Receives FDA Breakthrough Therapy Designation for CTP-543 for the Treatment of Alopecia Areata

Lead Product(s): Deuterated Ruxolitinib

Therapeutic Area: Dermatology Product Name: CTP-543

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 08, 2020

Details:

FDA Breakthrough Therapy Designation for CTP-543 is supported by positive data from a Phase 2 clinical trial in patients with moderate-to-severe alopecia areata.

AnaptysBio

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

AnaptysBio Announces Orphan Drug Designation of Imsidolimab For Treatment of Generalized Pustular Psoriasis

Lead Product(s): Imsidolimab

Therapeutic Area: Dermatology Product Name: ANB019

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 08, 2020

Details:

U.S. Food and Drug Administration (FDA) has granted orphan drug designation for imsidolimab, the company’s proprietary anti-interleukin-36 receptor (IL-36R) antibody, for the treatment of patients with GPP.

AOBiome Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

AOBiome Reports Successful Clinical Trials in Pruritus Associated with Atopic Dermatitis

Lead Product(s): B244

Therapeutic Area: Dermatology Product Name: B244

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 30, 2020

Details:

The adult trial was a double blind, placebo controlled, multicenter, Phase 2a study of B244, a first-in-class, topical formulation of beneficial ammonia oxidizing bacteria, delivered as a topical spray twice daily for 28 days.

Arcutis Biotherapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Arcutis Enrolls Last Patient in Phase 2 Proof of Concept Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatme...

Lead Product(s): Roflumilast

Therapeutic Area: Dermatology Product Name: ARQ-154

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 22, 2020

Details:

Roflumilast foam is a once-daily topical foam formulation of a highly potent and selective phosphodiesterase type 4 inhibitor (PDE4 inhibitor) that the Company is developing particularly to treat inflammatory dermatoses in hair-bearing areas of the body such as the scalp.

CARA Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Cara Therapeutics Completes Interim Statistical Assessment for KARE Phase 2 Trial of Oral KORSUVA in Atopic Dermatitis Patients

Lead Product(s): Difelikefalin

Therapeutic Area: Dermatology Product Name: Korsuva

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 17, 2020

Details:

Patient enrollment increased approximately 28% to maintain >80% statistical power for primary endpoint and key registration endpoint of >4-point improvement responder analysis.

Dermavant Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Dermavant Announces Publication in JAAD of Secondary Efficacy and Patient-Reported Outcomes in Phase 2b Clinical Trial of Tapinarof Cream

Lead Product(s): Tapinarof

Therapeutic Area: Dermatology Product Name: DMVT-505

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 16, 2020

Details:

The publication highlighted the secondary efficacy and patient-reported outcomes from its Dermavant's Phase 2b randomized clinical trial of tapinarof cream for the treatment of atopic dermatitis.

Vyome Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Vyome Therapeutics Announces Positive Results in Phase 2 Trial of VB-1953 for Moderate to Severe Acne

Lead Product(s): VB-1953

Therapeutic Area: Dermatology Product Name: VB-1953

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 16, 2020

Details:

Results demonstrate that VB-1953 with its dual mechanism of action directly kills resistant and non-resistant C. acnes strains while blocking inflammation through TLR-MD2 inhibition, is a safe and effective topical treatment for facial acne.

Find

Find Dermatology Drugs in Phase II Clinical Development in UNITED STATES

United States

Product Type

Companies

Alpine Immune Sciences

Alpine Immune Sciences Announces $60 Million Private Placement

Arcutis Biotherapeutics

Arcutis Enrolls Last Patient in Phase 2b Clinical Trial Evaluating ARQ-154 as a Potential Treatment for Scalp Psoriasis

Arcutis Biotherapeutics

Arcutis Initiates Patient Enrollment in the Phase 2b Portion of the Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand Eczema

Concert Pharmaceuticals

Concert Pharmaceuticals Receives FDA Breakthrough Therapy Designation for CTP-543 for the Treatment of Alopecia Areata

AnaptysBio

AnaptysBio Announces Orphan Drug Designation of Imsidolimab For Treatment of Generalized Pustular Psoriasis

AOBiome Therapeutics

AOBiome Reports Successful Clinical Trials in Pruritus Associated with Atopic Dermatitis

Arcutis Biotherapeutics

Arcutis Enrolls Last Patient in Phase 2 Proof of Concept Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatme...

CARA Therapeutics

Cara Therapeutics Completes Interim Statistical Assessment for KARE Phase 2 Trial of Oral KORSUVA in Atopic Dermatitis Patients

Dermavant Sciences

Dermavant Announces Publication in JAAD of Secondary Efficacy and Patient-Reported Outcomes in Phase 2b Clinical Trial of Tapinarof Cream

Vyome Therapeutics

Vyome Therapeutics Announces Positive Results in Phase 2 Trial of VB-1953 for Moderate to Severe Acne